Who Owns ResMed Company?

ResMed Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns ResMed today?

ResMed transformed from an Australian founder-led startup into a global sleep and respiratory care leader after its 1995 Nasdaq IPO, now serving over 160 countries with connected devices and software. Institutional investors, ETFs and retail holders dominate ownership while founder-family stakes remain present.

Ownership is widely dispersed across global institutions and ETFs, with board-level insiders retaining influence; ResMed reported FY2024 revenue near $4.6–$4.9 billion and market cap fluctuating around $25–$35 billion in 2024–2025.

Explore product and strategic context: ResMed Porter's Five Forces Analysis

Founders and Early Ownership of ResMed trace to 1989 when Dr Peter C. Farrell acquired rights to Professor Colin Sullivan’s CPAP technology from the University of Sydney and led initial capitalization and commercialization efforts; Farrell is documented as the principal founder and early controlling shareholder, later joined operationally by his son Michael 'Mick' Farrell.

Founder and Technology Origin

Dr Peter C. Farrell founded the company in 1989 after securing rights to CPAP technology developed by Professor Colin Sullivan at the University of Sydney.

Founding Role

Early records identify Farrell as the principal founder and controlling shareholder via holding entities that financed initial operations and IP commercialization.

Early Team

Clinicians and engineers from the University of Sydney medical community provided technical and clinical support during product development and validation.

Capital Sources

Initial funding combined founder capital, Australian private investors and strategic university/medical relationships before later U.S. scaling.

Re-domiciliation to U.S.

The company re-domiciled to the United States in the 1990s to expand manufacturing, distribution and access to capital markets.

Governance and IPO Path

Early governance emphasized IP assignment and clinical/regulatory control; pre-IPO secondary placements in the mid-1990s broadened the register but founder influence remained strong.

Founding equity percentages are not publicly itemized, but company filings and early documentation indicate Peter C. Farrell maintained majority control through holding entities while operational leadership transitioned toward Michael Farrell as the business scaled.

Key early ownership facts

Relevant points on early ResMed ownership and structure.

• Principal founder: Dr Peter C. Farrell; majority stake originally held via holding entities.
• Technology origin: CPAP device by Professor Colin Sullivan, University of Sydney (licensed to Farrell).
• Early capital: founder funds, Australian private investors and university/medical strategic partners.
• Governance: board aligned to clinical/scientific roadmap; no widely reported founder disputes before IPO.

For context on competitive positioning and how ownership shaped strategy see Competitors Landscape of ResMed; for 2024–2025 public data on who owns ResMed, refer to SEC filings and institutional holdings summaries showing major institutional investors and top 10 shareholders disclosed in annual proxy statements and 13F filings.

ResMed SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Key events shaping ResMed ownership include the 1995 IPO on Nasdaq, subsequent ASX cross-listing via CDIs, rapid CPAP adoption and reimbursement tailwinds in the 2000s–2010s, and the 2016–2023 software-focused acquisitions that broadened the equity story toward SaaS and increased institutional and passive investor participation.

Current register (2024–2025) is broadly held by U.S. and Australian institutions and ETFs; no single controller exists, with top holders typically in the 4–9% range and combined passive ownership forming a substantial double-digit share; insider holdings, including founder-family and executives, sit in the low-single-digit percent range.

Ownership evolution: key takeaways

The transition from founder concentration to diversified institutional ownership changed strategic priorities toward recurring revenue, capital discipline and ESG reporting.

• 1995 IPO established public governance and scaled manufacturing
• Index inclusions (MSCI, S&P) boosted passive ResMed ownership
• 2016–2023 SaaS deals raised share count and attracted growth funds
• Top institutional holders (Vanguard, BlackRock, State Street, Fidelity, AustralianSuper) dominate register

For a deeper look at ResMed strategy that influenced investor interest and ownership trends see Marketing Strategy of ResMed

ResMed PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

ResMed's board (2024–2025) is chaired by founder Dr. Peter C. Farrell with Michael “Mick” Farrell as CEO and director; the board is majority independent and composed of medtech, software, reimbursement, and global operations experts who oversee audit, compensation, and nominating/governance functions.

ResMed ownership reflects a one-share-one-vote common equity model traded on Nasdaq with CDIs on the ASX; institutional investors and large passive funds hold most shares while no single controlling shareholder exists, so voting influence arises from share accumulation and proxy dynamics.

Board composition and voting power — key points

The board blends founder continuity with a majority-independent slate; voting outcomes depend on institutional holders, proxy advisors, and aggregated share stakes rather than special voting rights.

• Governance: majority-independent board with specialized committees
• Voting structure: one-share-one-vote; no dual-class or golden shares
• Influence: large passive managers and active institutional investors drive outcomes
• Proxy dynamics: ISS and Glass Lewis materially affect close votes

As of mid-2025 the top institutional holders included Vanguard, BlackRock, and State Street as part of the ResMed largest shareholders list; insider ownership (including Mick Farrell and family) is meaningful but well below a majority, aligning management incentives without concentrated control — see related analysis in Target Market of ResMed.

ResMed Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

ResMed ownership since 2021 shifted toward larger institutional positions as device-market share gains and recurring-software additions attracted passive and active funds; insider stakes remain low-single digits and no controlling shareholder has emerged.

Institutional ownership trends: as of mid‑2025 filings, top institutional holders remain U.S. mutual funds and ETFs alongside major Australian superannuation funds, collectively owning a majority of free‑float shares; retail and insider stakes represent a small minority.

Demand shift after Philips recall

The Philips 2021 CPAP recall increased ResMed's market share and boosted revenue and operating cash flow, supporting index inflows and higher institutional allocations.

GLP‑1 driven valuation swings

Obesity‑drug headlines caused sharp valuation swings in 2023; subsequent clinical and market data through 2024–2025 confirmed a substantial untreated OSA population, tempering decline.

M&A tilting to SaaS

Acquisitions like MEDIFOX DAN in 2022–2023 increased recurring‑revenue weight; institutional investors favoring diversified revenue profiles raised exposure to ResMed.

Capital allocation

FY2024–FY2025 cash flow prioritized debt reduction and R&D while maintaining buybacks and dividends; buybacks modestly boosted concentration without changing control.

For additional context on strategy and register implications see Growth Strategy of ResMed

ResMed Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔